TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

KUVAN

SAPROPTERIN DIHYDROCHLORIDE
Approved 2007-12-13
3
Indications
--
Phase 3 Trials
2
Priority Reviews
18
Years on Market

Details

Status
Prescription
First Approved
2007-12-13
Routes
ORAL
Dosage Forms
POWDER, TABLET

Companies

Active Ingredient: SAPROPTERIN DIHYDROCHLORIDE

KUVAN Approval History

Loading approval history...

What KUVAN Treats

2 indications

KUVAN is approved for 2 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hyperphenylalaninemia
  • Phenylketonuria
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

KUVAN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

KUVAN ® is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe-restricted diet. KUVAN is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin‑ (BH4‑) responsive Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe‑restr...

KUVAN Patents & Exclusivity

Latest Patent: Apr 2033

Patents (12 active)

US9216178*PED Expires May 1, 2033
US9216178 Expires Nov 1, 2032
US7566462*PED Expires May 16, 2026
US8003126*PED Expires May 16, 2026
US7566462 Expires Nov 16, 2025
US8003126 Expires Nov 16, 2025
+ 2 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.